9. BIBLIOGRAFIA
1.
Freeman HJ. Comparison of Longstanding Pediatric-Onset and Adult-Onset Crohn’s Disease. Journal of Pediatric Gastroenteroly and Nutrition 2004; 39(2):183-6.2.
Eidelwein AP, Thompson R, Fiorino K, Abadom V, Oliva-Hemker M. Disease presentation and clinical course in black and white children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007; 44(5):555-60 3. Satsangi J, Silverberg MS, Vermeire S, Colombel JF The Montreal classification of inflammatory bowel disease:controversies, consensus and implications. Gut 2006; 55: 749-753
4. Dubinsky M. Special issues in pediatric inflammatory bowel disease. World J Gastroenterol 2008; 14(3): 413- 420
5. Diefenbach KA, Breuer CK. Pediatric Inflammatory Bowel Disease. World J Gastroenterol 2006 May 28; 12(20):
3204-3212.
6.
Russell MG. Changes in the incidence of inflammatory bowel disease: what does it mean? Eur J Intern Med 2000; 11:191-67.
Sood A. Midha V, Sood N, Bhatia As, Avasthi G. Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut 2003; 52(11):1587-90.8. Logan RF. Inflammatory bowel disease incidence: up, down or unchanged? Gut 1998;48:309-11
9.
Gearry RB, Richardson A, Frampton CM, Collett JA, Burt MJ, Chapman BA, Barclay ML.High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm Bowel Dis.2006;12(10):936-43
10.
Russel MG, Stockbrugger RW. Epidemiology of inflammatory bowel disease: an update. Scand J. Gastroenterol 1996;31(5):417-2711.
Loftus CG, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ 3rd, Sandborn WJ. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940- 2000.Inflamm Bowel Dis. 2007;13(3):254-6112.
Lakatos L, Mester G, Erdelyi Z, Balogh M, Szipocs I, Kamaras G, Lakatos PL. Striking elevation in incidence and prevalence of inflammatory bowel disease in a province of western Hungary between 1977-2001.World J Gastroenterol. 2004;10(3):404-913.
Leong RW, Lau JY, Sung JJ. The epidemiology and phenotype of Crohn's disease in the Chinese population.Inflamm Bowel Dis. 2004; 10(5): 646-51
14.
Sung JJ, Hsu RK, Chan FK, Liew Ct, Lau JW, Li AK. Crohn’s disease in the Chinese population. An experience from Honk Kong. Dis Colon Rectum 1994; 37:1307-0915. Lee Ym, Fock K, SeeSJ, Ng TM, Khor C, Teo EK. Racial diffrences in the prevalence of ulcerative colitis and Crohn’s disease in Singapore. J Gastroenterol Hepatol 2000; 15:622-5
16.
Jiang L, Xia B, Li J, YE M Yan W, Deng C et al Retrospective survey of 452 patients with inflammatory bowel disease in Wuhan city, central China. Inflamm Bowel Dis 2006; 12: 212-717.
Russel MG. Changes in the incidence of inflammatory bowel disease: what does it mean? Eur J Intern Med 2000; 11:191-618. Griffiths AM. Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol 2004;18: 509-23
19. Pappa HM, Semrin G, walzer TR, Grand Rj. Pediatric inflammatory bowel disease. Curr Opin Gastroenterol 2004; 20:33-40
20. Sawezenko A, Sandhu BK, Presenting features of inflammatory bowel disease in Great Britain and ireland.
Arch Dis Child 2003; 88: 995-1000
21. Phavichitr N, Cameron DJ, Catto-Smith AG. Increasing incidence of Crohn's disease in Victorian children.J Gastroenterol Hepatol. 2003;18(3):329-32
22. Pinsk V, Lemberg DA, Grewal K, Barker CC, Schreiber RA, Jacobson K. Inflammatory bowel disease in the South Asian pediatric population of British Columbia. Am J Gastroenterol. 2007; 102(5):1077-83
23.
Castro M, et al. Inflammatory bowel disease in children and adolescents in Italy: Data from the pediatric national IBD register (1996-2003). Inflamm Bowel Dis. 2008;14(9):1246-52.24. Heyman MB, Kirshner BS, gold BD, Ferry G, Baldassano R. CohenSA et al Children with early onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr 2005; 146: 35-40
25.
Canniotto Z, Berti I, Martelossi S, Bruno I, Giurici N, Crovella S, Ventura A, IBD and IBD mimicking enterocolitis in children younger than 2 years of age. Eur J Pediatr 2008 Jun 11.26. Loftus Jr EV, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am. 2002;
31(1): 1-20
27.
Karban A, Itay M. Davidovich O, Leshinsky-Silver E, Kimmel G, fidder H. et al. Risk factor for perianal Crohn’s disease: the role of genotype, phenotype, and ethnicity. Am J Gastroenterol 2007; 102: 1702-828.
Carr I, Mayberry JF. The effects of migration on ulcerative colitis: a three-year prospective study among Europeans and first- and second- generation South Asians in Leicester(1991-1994). Am J Gastroenterol. 1999;94(10):2918-22
29. Baumgart DC, Carding SR Inflammatory bowel disease: cause and immunobiology, Lancet 2007; 369:1627-40 30. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J et al. Association of NOD 2 leucine rich
repeat varians with susceptibility to Crohn’s disease. Nature 2001; 411: 599-603
31.
Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S et al. association between insertion mutation in NOD2 gene and Crohn’s disease in German and British population. Lancet 2001; 357: 1925-832.
Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001; 411: 603-633. Inohara N, Nunez G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol 2003; 3: 371-82
34. Inohara N, Ogura Y, Fontalba A et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn’s disease. J Biol Chem 2003; 278: 5509-12
35. Abbott DW, Wilkins A, Asara JM, Cantley LC. The Crohn’s disease protein, NOD2, requires RIP2 in order to induce ubiquitination of a novel site of NEMO. Curr Biol 2004; 14: 2217-27
36.
DeMesquita MB, Civitelli F., Levine A, Epidemiology, genes and inflammatory bowel diseases in childhood, Digestive and liver disease 2008; 40(1):3-1137. Sands BE Inflammatory bowel disease: past, present, and future. J Gastroenterol 2007; 42:16-25
38. Arnott ID, Nimmo ER, Drummond HE, Fennell J, Smith BR, MacKinlay E, et al. NOD2/CARD15, TLR4 and CD14
mutations in Scottish and Irish Crohn’s disease patients: evidence for genetic heterogeneity within Europe?
Genes Immun 2004; 5: 417-25
39. Gaya DR, Russell RK, Nimmo ER, Satsangi J. New genes in inflammatory bowel disease : lesson for complex disease? Lancet 2006; 367: 1271-84
40.
Levine A, Karban A, Eliakim R, Shaoul R, Reif S, Pacht A et al. A polymorphism in the TNF-alpha promoter gene is associated with pediatric onset and colonic localization of Crohn’s disease. Am J Gastroenterol 2005; 100:407-13
41.
Juyal G, Amre D, Midha V, Sood A, Seidman E, Thelma BK. Evidence of allelic heterogeneity for associations between the NOD2/CARD15 gene and ulcerative colitis among North Indians. Aliment Pharmacol Ther. 2007 Nov 15; 26 (10): 1325-3242.
Ferraris A, Knafelz D, Torres B, Fortina P, Castro M, Dallapiccola B. Analysis of Card 15 gene variants in Italian pediatric patients with inflammatory bowel diseases. J Pediatr. 2005; 147(2):272-3.43. Hugot JP, Alberti C, Berrei D, Bingen E, Cézard JP, Crohn’s disease: the cold chain hypotesis. Lancet 2003; 326;
2012-15
44.
Champagne CP, Laing RR, Roy D, Assanta MA. Psychrotrophs in dairy products; the effects and their control.Crit Rev Food Sci Nutr 1994; 34: 1-30
45.
Abraham C, Cho JH, Bugging of the intestinal mucosa, N Engl J Med. 2007; 357(7):708-1046. Davis RL, Kramarz P, Bohlke K et al, Measles-mumps-rubella and other measles containg vaccine do not increase the risk for inflammatory bowel disease: a case control study from the Vaccine Safety Datalink project. Arch Pediatr Adolesc Med 2001; 155:354-59
47. Garn H, Renz H Epidemiological and immunological evidence for the hygiene hypotesis. Immunobiology 2007;
212: 441-52
48. Radon K, Windstetter D, Poluda AL, et al Contact with farm animals in early life and juvenile inflammatory bowel disease: a case control study. Pediatrics 2007; 120: 354-61
49.
Thomas GA, Rhodes J, Green JT. Inflammatory bowel disease and smoking—a review. Am J Gastroenterol 1998; 93: 144-950.
Koutroubakis IE, Vlachonikolis IG, Kouroumalis EA. Role of appendicitis and appendicectomy in the pathogenesis of ulcerative colitis: a critical review. Inflamm Bowel Dis 2002; 8: 277-8651. Andersson RE, Olaison G, Tysk C, et al Appendectomy and protection against ulcerative colitis. N Engl J Med 2001; 344: 808-14
52.
Cosnes J, Seksik P, Nion-Larmurier I, Beaugerie L, Genere JP. Prior appendectomy and the phenotype and corse of Crohn’s disease. World J gastroenterol 2006; 12: 1235-4253. Colombel JF, Watson AJM, Neurath MF, the 10 remaing mysteries of inflammatory bowel disease, Gut 2008;
57; 429-43
54. Karban A, Eliakim R. Effect of smoking on inflammatory bowel disease: is it disease or organ specific? World J Gastroenterol 2007; 13: 2150-2
55.
Wakefield AJ, Sawyerr Am, Dhillon AP, et al. Pathogenesis of Crohn’s disease: multifocal gastrointestinal infarction. Lancet 1989; 2: 1057-6256.
Hatoum OA; Binino DG, Otterson MF et al. Acquired microvascular dysfunction in inflammatory boweldisease: loss of nitric oxide mediated vasodilation. Gastroenterology 2003; 125: 58-69
57.
Watson AJ. In vivo single-photon emission computer tomography imaging of apoptosis in Crohn’s disease and anti-tumor necrosis factor therapy. Gut 2007; 56: 461-358.
Bolivant M, Marini M, Di Felice G et al. Lamina propria T cells in Crohn’s disease and other gastrointestinal inflammation show detective CD2 pathway-induced apoptosis. Gastroenterology 1999; 116: 557-6559.
Zinnie IA, Campell BJ, Taylor BA, et al. Stimulation of colonic mucin synthesis by corticosteroids and nicotine.Clin Sci (Lond) 1996; 91: 359-64
60.
Louvet B, Buisine MP, Desreumaux P, et al. Transdermal nicotine decreases mucosal IL-8 expression but has no effect on mucin gene expression in ulcerative colitis. Inflamm Bowel disease 1999; 5:174-8161.
Sadis C, Teske G, Stokman G et al. Nicotine protects kidney from renal ischemia/reperfusion injury through the colinergic anti-inflammatory pathway PLoS ONE 2007; 2:e46962.
Holland N, Dong J, Garnett E, Shaikh N et al. Reduced intracellulare T-Helper 1 Interferon-Gamma in blood of newly diagnosed children with Crohn’s Disease and age-related changes in Th1/Th2 cytochine profiles. Pediatr Res 63: 257-262, 200863. Orchard TR, Jewell DA. Extraintestinal manifestations In IBD: Sartor R, Sandborn WJ eds Kirner’s inflammatory bowel disease. Edinburg: Saunders, 2004: 658-72
64. Orchard TR, Chua CN, Ahmad T et al, Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 2002; 123: 714-8
65. Newby EA, Croft NM, Green M, Hassan H, Heuschkel RB, Jenkins H, Casson DH. Journal of Pediatric Gastroenterology and Nutrition 46:539-545
66. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and estabilished and evolving therapies. Lancet 2007; 369:1641-57
67. Shamir R, Phillip M, Levine A. Growth Retardation in Pediatric Crohn’s Disease: Pathogenesis and Interventions. Inflamm Bowel Dis 2007:13:620-628
68. Sylvester FA, Wyzga N, hyams JS et al, Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease, Inflamm Bowel Dis.2007,13,42-50
69. Kappelman MD, Bousvaros A. Nutritional concerns in pediatric inflammatory bowel disease patients. Mol Nutr Food Res 2008, 52 (8): 867-74
70. Differentiating Ulcerative colitis from Crohn disease in children and Young Adults: Report of a Working Group of the North American Society for Pediatric Gastroeneterology, Hepatology, and Nutrition and the Crohn’s and Colitis Foundation of America. Journal of Pediatric Gastroenterology and Nutrition 44: 653-64
71. Inflammatory Bowel Disease Working Group of ESPGHAN. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-the Porto criteria. J Pediatric Gastroeneterol Nutr 2005; 41:1-7 72. Rachmilewitz D. Coated Mesalazine (5-aminosalicylic acid) versus Sulphasalazine in the treatment of active
Ulcerative Colitis: a randomized trial. Br Med J 1989; 298: 82-6
73.
Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, Walters TD, Zachos M, Mamula P, Beaton DE, Steinhart AH, Griffiths A Development, validation, and evaluation of a pediatric ulcerative colitis activity index:a prospective multicenter study. Gastroenterology. 2007;133(2):423-32
74. Katz JA.Treatment of inflammatory bowel disease with corticosteroids. Gastroenterol Clin North Am. 2004;
33(2):171-89, vii
75. Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol. 2008; 14(3):354-77
76.
Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007; 5(1):103-10 77. Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG. The effectiveness of budesonidetherapy for Crohn's disease. Aliment Pharmacol Ther. 2002; 16(8):1509-17
78.
Otley A, Steinhart AH. Budesonide for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD000296. DOI: 10.1002/14651858.CD000296.pub279.
Simms L, Steinhart AH. Budesonide for maintenance of remission in Crohn's disease.CochraneDatabaseofSystematicReviews2001,Issue1.Art.No.:CD002913.DOI:10.1002/14651858.CD002 91380.
Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease.Cochrane Database of Systematic Reviews 2001, Issue 3. Art. No.: CD000542. DOI:
10.1002/14651858.CD000542.pub2 Date of last subtantive update: October 03. 2006
81.
Akobeng AK, Thomas AG. Enteral nutrition for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD005984. DOI: 10.1002/14651858.CD005984.pub282.
Borrelli O, Cordischi L, Cirulli M, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn’s disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006; 4: 744- 5383. Akobeng AK. Crohn’s disease: current treatment options. Arch Dis Child 2008; 93: 787-792.
84.
Lochs H, Dejong C, Hammarqvist F, et al. ESPEN Guidelines on Enteral Nutrition Gastroenterology. Clin Nutr.2006; 25: 260-74.
85.
Turner D, Zlotkin SH, Shah PS, et al. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn’s disease. Cochrane Database of Systematic Review 2007; (2).86. Desreumaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid – new evidence.
Aliment Pharmacol Ther 2006 ; 24 Suppl 1: 2-9
87. Bremner AR, Beattie RM. Recent advances in the medical therapy of crohn’s disease in childhood. Expert Opin Pharmacother(2007) 8(15): 2553-2568
88.
Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.Cochrane Database of Systematic Reviews 1997, Issue 4. Art. No.: CD000543. DOI:
10.1002/14651858.CD000543.pub2. Date of last subtantive update: February 13. 2006
89.
Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.Cochrane Database of Systematic Reviews 1997, Issue 4. Art. No.: CD000544.
DOI:10.1002/14651858.CD000544.pub2. Date of last subtantive update: February 13. 2006
90.
Marshall JK, Irvine EJ. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol 2000; 95 :1628-163691.
Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 1998, Issue 3. Art. No.:CD000545. DOI:10.1002/14651858.CD000545
92.
Holtmann MH, krummenauer F, Claas C et al. Long-term effectiveness of azathioprine in IBD beyond 4 years: aEuropean multicenter study in 1176 patients. Dig Dis Sci. (2006) 51:1516-1524
93.
Timmer A, McDonald JWD, MacDonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD000478. DOI:10.1002/14651858.CD000478.pub2
94.
Jani N, Regueiro MD. Medical therapy for ulcerative colitis. Gastroenterol Clin North Am 2002; 31: 147-166 95. Pierik M, Rutgeerts P, Vlietinck R, Vermeire S. Pharmacogenetics in inflammatory bowel disease.World JGastroenterol. 2006; 12(23):3657-67
96.
Uhlen S, Belbouab R, Naresbski K et al. Efficacy of methotrexate in pediatric Crohn’s disease: a French multycenter study. Inflamm Bowel Dis (2006) 12:1053-105797.
Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Koval J, Wong CJ, Hopkins M, Hanauer SB, McDonald JW. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med. 2000;342(22):1627-32.
98.
Arora S, Katkov W, Cooley J, Kemp JA, Johnston DE, Schapiro RH, Podolsky D. Methotrexate in Crohn's disease:results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology. 1999; 46(27):1724-9
99.
Chande N, MacDonald JK, McDonald JWD. Methotrexate for induction of remission in ulcerative colitis.Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD006618. DOI:
10.1002/14651858.CD006618.pub2
100. Oren R, Arber N, Odes S, Moshkowitz M, Keter D, Pomeranz I, Ron Y et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996; 110: 1416-1421 101. Jani N, Regueiro MD. Medical therapy for ulcerative colitis. Gastroenterol Clin North Am 2002; 31: 147-166 102. Castro M, Papadatou B, Ceriati E, Knafelz D, De Angelis P, Ferretti F, Gambarara M, Diamanti A, De Peppo F,
Rivosecchi M. Langenbecks Arch Surg. 2007; 392(2):161-4.
103. Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev. 2008; (3): CD007216.
104. Lemann M, Mary JY, Duclos B et al. Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial: Gastroenterology 2006; 130:1054-61
105. Schroder O, Blumenstein I, Stein J. Combinino infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn’s disease: a controlled pilot study. Eur J Gastroenterol Hepatol 2006; 18: 11-6
106. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008; 371(9613):660-7
107. Hyams J, Crandall W, Kugathasan S, Griffiths A. Et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 2007; 132: 863-73
108. Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis. 2007; 13(8):1024-30
109. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD006893. DOI:
10.1002/14651858.CD006893
110. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007; 146(12):829-38
111. Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OØ, Innes A; CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease Gastroenterology. 2005; 129(3):807-18.
Erratum in: Gastroenterology. 2005 Nov;129(5):1808
112. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ; PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357(3):239-50.
113. Peyrin-Bidroulet L, Desreumaux P, Sandborn WJ, Colombel JF. Crohn’s disease: beyond antagonists of tumour necrosis factor. Lancet 2008; 372: 67-81.
114. Karen Honey. The comeback kid: TYSABRI now FDA approved for crohn disease. J Clin Invest. 2008; 118 (3):
825-826
115. Traynor K. FDA advisers endorse natalizumab for Crohn’s Disease. Am J Health Syst Pharm. 2007; 64: 1886- 1890.
116. Schraut WH. The surgical management of Crohn’s disease. Gastroenterol Clin North Am 2002; 31:255-263
117.
Baldassano RN, Piccoli DA. Inflammatory bowel disease in pediatric and adolescent patients.Gastroenterol Clin North Am 1999; 28:445-458118.
Munkholm P. langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistence and dependacy in Crohn’s disease. Gut 1994; 35: 360-362119.
Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population based study: Gastroenterology 2001; 121: 255-260 120. Freeman HJ, Colon cancer and Crohn’s disease. World J Gastroenterol 2008 14 (12): 1810-1811121. Zisman TL, Rubin DT, Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol 2008; 14 (17): 2661-2669
122. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and displasia risk:
asystematic review and metaanalysis of observational studies. Am J Gastronterol 2005; 100: 1345-1353 123. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in
patients with ulcerative colitis and primari sclerosino cholangitis. Gastroenterology 2003; 124:889-893
124.
Israeli E, Grotto I, Gilburd B et al Anti-saccaromyces cerevisiae and antineutrophil cytoplasmatic antibodies as predictor of inflammatory bowel disease. Gut 2005; 54 : 1232-36.125.
Van Kruingen HJ, ganley LM, Freda BJ. The role of Peyer patches in the age related incidence of Crohn’s disease. J Clin Gastroenterol 1997; 25: 470-5126.
Neut C, Bulois P, Desreumaux P et al. Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn’s disease. Am J Gastroenterol 2002; 97: 939-46.127. Matthews SJ, McCoy C. Thalidomide: a review of approved and investigational uses. Clin Ther. 2003 Feb;
25(2):342-95
128. Erikson T, BjorkmanS, Roth B, Hoglund P.Clinical pharmacology of thalidomide, eur J Clin pharmacol 2001:57:
365-376
129. Franks ME, Macpherson, Figg WD, Thalidomide, Lancet 2004 May 29;363(9423):1802-11.
130. Heney D, Norfolk DR, Wheeldon J, Bailey CC, Lewis IJ et al. Thalidomide treatment for chronic graft-versus- host disease. Br J Dermatol 1991; 78:23-27.
131. Chintagumpala M et al. Phase I and pharmacokinetic study of thalidomide and carboplatin in children with cancer. J Clin Oncol 2004;22:4394-4400
132. Marriott JB, Clarke IA, Dredge K, Muller G, Stirling D, Dalgleish AG. Thalidomide and its analogues have distinct and opposing effetcts on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. ClinExp Immunol 2002; 130: 75-84
133. Jacobson JM, Greenspan JS, Spritzler J, Netter N, Fahey JL, Jackson JB, Fox L, et al. Thalidomide for treatment of oral aphtous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997,21:1487- 1493
134. McHugh SM, RifkinIR, Deighton J, et al The immunosopressive drug thalidomide induces T helper cell type 2 (TH2) and concomitantly inhibits TH1 cytokine production in mitogen- and antigen stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995; 99: 160-7
135.
Haslett PA, Roche P, Butlin CR, Macdonald M, Shrestha N, Manandhar R,Lemaster J, Hawksworth R, Shah M, Lubinsky AS, Albert M, Worley J, Kaplan G. Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation. J Infect Dis. 2005; 192(12):2045-53136.
Villahermosa LG, Fajardo TT Jr, Abalos RM, Balagon MV, Tan EV, Cellona RV, Palmer JP, Wittes J, Thomas SD, Kook KA, Walsh GP, Walsh DS. A randomized, double-blind, double-dummy, controlled dose comparison ofthalidomide for treatment of erythema nodosum leprosum. Am J Trop Med Hyg. 2005;72(5):518-26137. Crawford CL. No role for thalidomide in the treatment of leprosy. J Infect Dis. 2006; 193(12):1743-4; author reply 1744-5
138.
Marchetti F, Lenhardt A, Lazzerini M, Liubich M, Ventura A, La talidomide, Medico e bambino 2003; 22:517- 523139.
Tolland JP, Devereux C, Jones FC, Bingham EA Sclerodermatous chronic graft-versus-host disease--a report of four pediatric cases. Pediatr Dermatol.2008; 25(2):240-4140.
Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997; 336(21):1487-93141.
Ramirez-Amador VA, Esquivl-Pedraza L et al. Thalidomide as therapy for human immunodeficiency virus- related oral ulcers: a double-blind placebo-controlled clinical trial. Clin Infect Dis 1999 Apr; 28 (4): 892-4 Revuz J, Guillaume JC, Janier M, Hans P, Marchand C, Souteyrand P, Bonnetblanc JM, Claudy A, Dallac S, Klene C, et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol. 1990;126(7):923-7
142.
Revuz J, Guillaume JC, Janier M, Hans P, Marchand C, Souteyrand P, Bonnetblanc JM, Claudy A, Dallac S, Klene C, et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol. 1990;126(7):923-7143. Marque M, Guillot B, Bessis D. Thalidomide for treatment of PFAPA syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103(3):306-7
144.
Cuadrado MJ, Karim Y, Sanna G, Smith E, Khamashta MA, Hughes GR. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med. 2005; 118(3):246- 50145.
Ordi-Ros J, Cortés F, Cucurull E, Mauri M, Buján S, Vilardell M. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J Rheumatol. 2000; 27(6):1429-33146. Atra E, Sato EI. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol. 1993; 11(5):487-93
147.
Gardner-Medwin JM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis. 1994; 53(12):828-32148.
Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, Zwingenberger K Yazici H. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo- controlled trial. Ann Intern Med. 1998;128(6):443-50149.
Kari JA, Shah V, Dillon MJ. Behçet's disease in UK children: clinical features and treatment including thalidomide. Rheumatology (Oxford). 2001; 40(8):933-8150.
Yasui K, Uchida N, Akazawa Y, Nakamura S, Minami I, Amano Y, Yamazaki T. Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease. Inflamm Bowel Dis. 2008; 14(3):396-400151. Kobayashi K, Ueno F, et al. Develpoment of consensus statements for the diagnosis and management of intestinal Behçet’s disease using a modified Delphy approach. J Gastroenterol. 2007; 42(9): 737-45
152. Hamza MH. Treatment of Behçet's disease with thalidomide. Clin Rheumatol. 1986; 5(3):365-71
153.
García-Carrasco M, Fuentes-Alexandro S, Escárcega RO, Rojas-Rodriguez J, Escobar LE Efficacy of thalidomide in systemic onset juvenile rheumatoid arthritis. Joint Bone Spine. 2007; 74(5):500-3154. Lehman TJ, Striegel KH, Onel KB.Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis. J Pediatr. 2002; 140(1):125-7
155.
Huang F, Gu J, Zhao W, Zhu J, Zhang J, Yu DT. One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum. 2002; 47(3):249-54156. Wei JC, Chan TW, Lin HS, Huang F, Chou CT. Thalidomide for severe refractory ankylosing spondylitis: a 6- month open-label trial. J Rheumatol. 2003; 30(12):2627-31
157. Davis JC Jr. Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis. Semin Arthritis Rheum. 2005; 34(4):668-77
158.
Nguyen YT, Dupuy A, Cordoliani F, Vignon Pennamen MD, Lebbé C, Morel P, Rybojad M. Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol. 2004; 50(2):235-41159.
Hammond ER, Kaplin AI, Kerr DA. Thalidomide for acute treatment of neurosarcoidosis. Spinal Cord. 2007;45(12):802-3
160.
Judson MA, Silvestri J, Hartung C, Byars T, Cox CE. The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006; 23(1):51-7161. Damaj G, Bernit E, Ghez D,Claisse, Schleinitz N,Harlè JR, Canioni D, Ermine O, Thalidomide in advanced mastocytosis. British J Haematol 2008, 141, 249-253
162.
Wu JJ, Huang DB, Pang KR, Hsu S, Tyring SK. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol. 2005; 153(2):254-73163. Drenth JP, Vonk AG, Simon A, Powell R, Van Der Meer JW. Limited efficacy of thalidomide in the treatment of
febrile attacks of teh hyper-IgD and periodic fever syndrome : a randomized, double-blind, placebo controled trial. J Pharmacol Exp Ther 2001; 298: 1221-6
164. Wolknstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352: 1586-9
165. Schoeman JF, Springer P, van Rensburg AJ, Swanevelder S, Hanekom WA, Haslett PA, Kaplan G. Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study. J Child Neurol.2004; 19(4):250-7
166.
Seldin DC, Choufani EB, Dember LM, Wiesman JF, Berk JL, Falk RH, O’Hara C, fennessey S, Finn KT, Wright DG, Skiner M, Sanchorawala V. tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated amyloidosis. Clin Lymphoma 2003; 3(4):241-6167. Pillemer SR, Leakan RA et al.Prominent adverse effects of thalidomide in Sjögren’s syndrome. Arthritis &
Rheumatism (Arthritis Care & Research) 2004, 51 (3): 505-506
168.
Dahut WL et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol. 2004;22(13):2532-9169.
Di Lorenzo G et al. Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial. Cancer Biol Ther. 2007;6(3):313-7170.
Amato RJ et al. A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer. Clin Genitourin Cancer. 2006; 4(4):281-6171.
Romero S et al. Phase II trial of thalidomide and daily oral dexamethasone for treatment of hormone refractory prostate cancer progressing after chemotherapy. Urol Oncol. 2007; 25(4):284-90172.
Amato RJ et al. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma. Cancer 2006; 106(7):1498-506173.
Amato RJ et al. Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: a pilot study. Invest New Drugs. 2006; 24(3):171-5174.
Lee CP et al. Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24(6):898-903175.
Elaraj et al. A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma. J Immunother. 2004; 27(4):259-64176.
Zang HG et al. A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer. Zhonghua Zhong Liu Za Zhi. 2007;29(3):228-31
177.
Ain KB et al. Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid. 2007; 17(7):663-70178.
Fine HA et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol. 2003; 21(12):2299-304179.
Kesari S et al. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol. 2008; 10(3): 300-8180.
Puduvalli VK et al. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol. 2008; 10(2):216-22181.
Turner CD et al. Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. J Neurooncol. 2007;82(1):95-101182.
Mita MM. et al. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. Cancer Chemother Pharmacol. 2007;59(2):165-74183.
Little RF et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol. 2000; 18(13):2593-602184.
Rubegni P et al. Thalidomide in the treatment of Kaposi's sarcoma. Dermatology. 2007; 215(3):240-4185.
Ben M'barek et al. A retrospective analysis of thalidomide therapy in non-HIV-related Kaposi's sarcoma.Dermatology. 2007; 215(3):202-5
186.
Chuah B et al. Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncol. 2007;46(2):234-8187.
Zhu AX et al. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist. 2005; 10(6):392-8188.
Hsu WC et al. Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma. Jpn J Clin Oncol. 2006; 36(2):93-9189.
Downs LS Jr. A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer. 2008 15;112(2):331-9190.
Miller AA et al. Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non- small cell lung cancer. J Thorac Oncol. 2006; 1(8):832-6191.
Pujol JL et al. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol.2007; 25(25):3945-51
192.
Tseng JE. et al. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer. 2001 Nov 1;92(9):2364-73 Colleoni M. et al. Metronomic low- dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer:antitumor activity and biological effects. Ann Oncol. 2006; 17(2):232-8
193.
Colleoni M. et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol. 2006; 17(2):232-8194.
Morabito A. et al. Thalidomide is inactive in heavily pretreated patients with metastatic breast cancer.Cancer J. 2005; 11(3):248-51
195.
Priolo T, Lamba LD, Giribaldi G, De Negri E, Grosso P, De Grandis E, Veneselli E, Buoncompagni A, Viola S, Alpigiani MG, Gandullia P, Calevo MG. Childhood thalidomide neuropathy: a clinical and neurophysiologic study. Pediatr Neurol. 2008; 38(3):196-9196.
Lazzerini M, Martelossi S, Marchetti F, Scabar A, Bradaschia F, Ronfani L, Ventura A. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results.Aliment Pharmacol Ther. 2007; 25(4):419-27
197. Chintagumpala M et al. Phase I and Pharmacokinetic Study of Thalidomide with Carboplatin in Children with Cancer. J Clin Onc 22:4394-4400
198. Mansfield JC, Parkes M, Hawthorne AB, Forbes A, Probert CS, Perowne RC, Cooper A, Zeldis JB, Manning DC, Hawkey CJ. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. Aliment Pharmacol Ther. 2007; 26(3):421-30
199.
Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology. 1999; 117(6):1271-7200. Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, Zeldis JB, Targan SR. An open- label pilot study of low-dose thalidomide in chronically active,steroid-dependent Crohn's disease.
Gastroenterology. 1999; 117(6):1278-87
201. Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut. 2002; 50(2):196-200
202. Bariol C, Meagher AP, Vickers CR, Byrnes DJ, Edwards PD, Hing M, Wettstein AR, Field A.Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease.J Gastroenterol Hepatol.
2002; 17(2):135-9
203.
Ahmed M, El-Hadi S, Jenkins HR. Thalidomide in Crohn disease and the risk of peripheral neuropathy. J Pediatr Gastroenterol Nutr. 2003; 37(4):522204.
Hegarty A, Hodgson T, Porter S. Thalidomide for the treatment of recalcitrant oral Crohn's disease and orofacial granulomatosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003; 95(5):576-85205. Sabate JM, Villarejo J, Lemann M, Bonnet J, Allez M, Modigliani R. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease.
Aliment Pharmacol Ther. 2002; 16(6):1117-24
206. Kane S, Stone LJ, Ehrenpreis E. Thalidomide as "salvage" therapy for patients with delayed hypersensitivity response to infliximab: a case series. J Clin Gastroenterol. 2002; 35(2):149-50
207.
Facchini S, Candusso M, Martelossi S, Liubich M, Panfili E, Ventura A. Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results. J Pediatr Gastroenterol Nutr.2001; 32(2):178-81
208.
Plamondon S, Ng SC, Kamm MA. Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies. Aliment Pharmacol Ther. 2007; 25(5):557-67209.
Kolivras A, De Maubeuge J, André J, Song M. Thalidomide in refractory vulvar ulcerations associated with Crohn's disease. Dermatology. 2003;206(4):381-3210.
Ginsburg PM, Dassopoulos T, Ehrenpreis ED. Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature. Ann Med. 2001; 33(8):516-25211.
Odeka EB, Miller V.Thalidomide in oral Crohn's disease refractory to conventional medical treatment. J Pediatr Gastroenterol Nutr. 1997; 25(2):250-1212.
Weinstein TA, Sciubba JJ, Levine J.Thalidomide for the treatment of oral aphthous ulcers in Crohn's disease. J Pediatr Gastroenterol Nutr. 1999; 28(2):214-6.213.
Fishman SJ, Feins NR, D'Amoto RJ, Folkman J.Thalidomide for Crohn's disease. Gastroenterology. 2000;119(2):596
214. Kabuki T, Ogimi C, Tanaka R, Ikematsu K, Joh K, Kagimoto S, Oh-Ishi T. Thalidomide therapy for infantile-onset Crohn's disease Nihon Rinsho Meneki Gakkai Kaishi. 2005; 28(2):92-8
215. Palencia G, Calderon A, Sotelo J. Thalidomide inhibits pentylenetetrazole-induced seizures. J Neurol Sci.
2007; 258(1-2):128-31
216.
John Coutsouvelis, Carmela E Corallo. Thalidomide-induced bradicardia and its management. MJA 2004; 180(7): 366-367)
217.
Fadhi IE, Gaddam V. et al. Bradycardia during therapy for multiple myeloma with thalidomide. Am J Cardiol.2004; 93 (8): 1052-5.
218. Marchetti F, Lazzerini M, Ventura A. A new opportunity for thalidomide? Further randomised controlled trials are necessary. Eur J Clin Pharmacol. 2004;60:607-8.
219. Bastuji-Garin S, Ochonisky S, Bouche P, Gherardi RK, Duguet C. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol 2002;119:1020-6
220. Chaudhry V, Cornblath DR, Corse A, Freimer M, Simmons-O'Brien E, Vogelsang G. Thalidomide-induced neuropathy. Neurology 2002;59:1872-5
221. Cavaletti G, Beronio A, Reni L, et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study.
Neurology. 2004;62:2291-3.
222. Pigott A, Casson D. Thalidomide in Crohn disease. J Pediatr Gastroenterol Nutr.2005 Feb;40:236.
223. Ghobrial IM, Rajkumar SV.Management of thalidomide toxicity. J Support Oncol. 2003;1:194-205
